AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu (trastuzumab deruxtecan) inched closer to a second-line HER2-positive breast cancer indication with the announcement of positive topline results of a Phase III study, thereby expanding an opportunity that was the subject of a nearly $7bn pact between the two companies in 2019.
A second-line approval would move Enhertu into a similar setting as Seagen Inc.’s Tukysa (tucatinib) as competition in the HER2-positive...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)